- Home
- RYI vs AUTL Comparison
RYI vs AUTL Comparison
Compare RYI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYI
- AUTL
- Stock Information
- Founded
- RYI 1842
- AUTL 2014
- Country
- RYI United States
- AUTL United Kingdom
- Employees
- RYI N/A
- AUTL N/A
- Industry
- RYI Metal Fabrications
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RYI Industrials
- AUTL Health Care
- Exchange
- RYI Nasdaq
- AUTL Nasdaq
- Market Cap
- RYI 661.1M
- AUTL 590.8M
- IPO Year
- RYI N/A
- AUTL 2018
- Fundamental
- Price
- RYI $21.56
- AUTL $2.17
- Analyst Decision
- RYI Hold
- AUTL Strong Buy
- Analyst Count
- RYI 1
- AUTL 3
- Target Price
- RYI $28.00
- AUTL $10.20
- AVG Volume (30 Days)
- RYI 279.1K
- AUTL 1.1M
- Earning Date
- RYI 02-20-2025
- AUTL 03-13-2025
- Dividend Yield
- RYI 3.42%
- AUTL N/A
- EPS Growth
- RYI N/A
- AUTL N/A
- EPS
- RYI 0.64
- AUTL N/A
- Revenue
- RYI $4,703,700,000.00
- AUTL $10,091,000.00
- Revenue This Year
- RYI N/A
- AUTL $851.83
- Revenue Next Year
- RYI $1.76
- AUTL $224.65
- P/E Ratio
- RYI $33.54
- AUTL N/A
- Revenue Growth
- RYI N/A
- AUTL 82.71
- 52 Week Low
- RYI $17.18
- AUTL $2.07
- 52 Week High
- RYI $36.15
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- RYI 52.23
- AUTL 41.81
- Support Level
- RYI $21.17
- AUTL $2.11
- Resistance Level
- RYI $23.50
- AUTL $2.26
- Average True Range (ATR)
- RYI 0.83
- AUTL 0.12
- MACD
- RYI 0.32
- AUTL 0.01
- Stochastic Oscillator
- RYI 47.80
- AUTL 27.78
About RYI Ryerson Holding Corporation
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority is from the United States.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.